To further test IGFBP3/TMEM219 blockade in a model that better mimics the chronic inflammation of CD, we used the DSS-mediated chronic colitis treatment model, in which colitis was induced with 3 cycles of oral DSS and ecto-TMEM219 was started after the colitis establishment at day +18 (Figure 4H). Here, IGFBP3 is linked to colitis.